Prognostic Role of Preoperative Chemotherapy in Liver-Limited Metastasis from Gastric Cancer
View abstract on PubMed
Summary
This summary is machine-generated.Preoperative chemotherapy improves survival for gastric cancer patients with liver metastases undergoing surgery. This approach is recommended, and its effectiveness helps guide surgical decisions for liver-limited metastasis.
Area Of Science
- Surgical Oncology
- Gastrointestinal Oncology
- Medical Oncology
Background
- Investigating the prognostic significance of preoperative chemotherapy in gastric cancer (GC) patients undergoing hepatectomy for liver-limited metastasis (LLM).
- Assessing the impact of neoadjuvant therapy on outcomes for patients with resectable LLM from GC.
Purpose Of The Study
- To evaluate the role of preoperative chemotherapy in improving overall survival (OS) for patients with LLM from GC.
- To determine if preoperative chemotherapy is an independent prognostic factor for hepatectomy in GC patients with LLM.
Main Methods
- Retrospective analysis of 52 patients with R0 or R1 resection for synchronous or metachronous LLM from GC.
- Comparison of outcomes between patients receiving preoperative chemotherapy (PC group) and those undergoing upfront surgery (US group).
Main Results
- The PC group demonstrated significantly longer overall survival (5-year OS: 47.6% vs. 24.8%, p=0.041).
- Preoperative chemotherapy was an independent favorable prognostic factor (HR: 0.445, p=0.036).
- Partial response to chemotherapy correlated with improved OS, and the PC group had higher rates of solitary recurrence and re-resection.
Conclusions
- Preoperative chemotherapy is a recommended treatment for patients with LLM from GC.
- Evaluating chemotherapy response aids in determining surgical indications for LLM in GC.

